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Summary
 
Stromelysin-3 is an unusual matrix metalloproteinase, being released in the active rather than
zymogen form and having a distinct substrate specificity, targeting serine proteinase inhibitors
(serpins), which regulate cellular functions involved in atherosclerosis. We report here that hu-
man atherosclerotic plaques (
 
n
 
 
 
5
 
 7) express stromelysin-3 in situ, whereas fatty streaks (
 
n
 
 
 
5
 
 5)
and normal arterial specimens (
 
n
 
 
 
5
 
 5) contain little or no stromelysin-3. Stromelysin-3 mRNA
and protein colocalized with endothelial cells, smooth muscle cells, and macrophages within
the lesion. In vitro, usual inducers of matrix metalloproteinases such as interleukin-1, inter-
feron-
 
g
 
, or tumor necrosis factor 
 
a
 
 did not augment stromelysin-3 in vascular wall cells. How-
ever, T cell–derived as well as recombinant CD40 ligand (CD40L, CD154), an inflammatory
mediator recently localized in atheroma, induced de novo synthesis of stromelysin-3. In addi-
tion, stromelysin-3 mRNA and protein colocalized with CD40L and CD40 within atheroma.
In accordance with the in situ and in vitro data obtained with human material, interruption of
the CD40–CD40L signaling pathway in low density lipoprotein receptor–deficient hyperlipi-
demic mice substantially decreased expression of the enzyme within atherosclerotic plaques.
These observations establish the expression of the unusual matrix metalloproteinase stromelysin-3
in human atherosclerotic lesions and implicate CD40–CD40L signaling in its regulation, thus
providing a possible new pathway that triggers complications within atherosclerotic lesions.
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T
 
he proteinase stromelysin-3 (MMP-11) belongs to the
matrix metalloproteinase (MMP)
 
1
 
 family, enzymes
which participate in tissue remodeling in a variety of dis-
eases, including tumor metastasis and invasion, arthritis, and
atherogenesis (1–8). In contrast to “classical” MMPs, se-
creted as inactive zymogens, stromelysin-3 is released as an
active enzyme (9, 10). The zymogen contains a unique 10–
amino acid insert between the pro and catalytic domain
that includes a recognition motif for furin, the Golgi-asso-
 
ciated pro protein convertase, which processes stromelysin-3
to its enzymatically active form during traversal through
the constitutive secretory pathway.
Stromelysin-3 was originally identified by differential
screening of cDNA libraries derived from an invasive breast
cancer surgical specimen and from benign breast fibroade-
noma (11). Stromelysin-3 mRNA and protein expression
correlates with the invasiveness of human carcinomas and
also occurs in some sarcomas or other nonepithelial tumors
(3, 12–15). These, as well as other studies (16–20), indi-
cated a crucial role for the proteinase in processes charac-
terized by extensive extracellular matrix turnover. Strome-
lysin-3, however, has a restricted substrate specificity
distinct from all other matrix metalloproteinases. The en-
zyme only weakly, if at all, degrades extracellular matrix
constituents such as laminin, fibronectin, and collagen (21,
22). Instead, substrates of stromelysin-3 include serine pro-
teinase inhibitors, termed serpins (23, 24).
 
1
 
Abbreviations used in this paper:
 
 
 
a
 
2
 
-AP, 
 
a
 
2
 
-antiplasmin; 
 
a
 
1
 
-AT, 
 
a
 
1
 
-anti-
trypsin; 
 
a
 
2
 
-M, 
 
a
 
2
 
-macroglobulin; 
 
a
 
1
 
-PI, 
 
a
 
1
 
-proteinase inhibitor; AT-III,
antithrombin III; EC, endothelial cells; FBS, fetal bovine serum; IGF,
insulin-like growth factor; IGFBP, insulin-like growth factor binding
 
protein; LDLR
 
2
 
/
 
2
 
, low density lipoprotein receptor deficient; MMP,
matrix metalloproteinase; MØ, macrophages; PMA, Phorbol-12 myristate
13-acetate; RT, reverse transcription; SMC, smooth muscle cells. 
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The serpin superfamily includes more than 60 proteins,
which can function as inhibitory mediators by acting as sui-
cide substrates for the respective enzyme, with the vast ma-
jority targeted towards the serine proteinases known to be
involved in extracellular matrix remodeling, regulation of
blood pressure, modulation of inflammatory responses, cell
migration and differentiation, fibrinolysis, or blood coagu-
lation (24). This group of serpins consists of single chain
proteins, such as 
 
a
 
1
 
-proteinase inhibitor (
 
a
 
1
 
-PI), 
 
a
 
1
 
-anti-
trypsin (
 
a
 
1
 
-AT), 
 
a
 
2
 
-antiplasmin (
 
a
 
2
 
-AP), 
 
a
 
2
 
-macroglobulin
(
 
a
 
2
 
-M), plasminogen activator inhibitor, antithrombin III
(AT-III), C1 inhibitor, angiotensinogen, etc. Most of these
serpins have known functions: 
 
a
 
1
 
-PI acts on elastolytic
proteases, such as leukocyte elastase, and cathepsin G (25,
26); 
 
a
 
1
 
-AT and 
 
a
 
2
 
-M are involved in lipoprotein catabo-
lism (27–29); 
 
a
 
1
 
-AT also inhibits renin and thus the renin–
angiotensinogen interaction (30); 
 
a
 
2
 
-AP and plasminogen
activator inhibitor are involved in the regulation of fibrin-
olysis; C1 inhibitor is essential for the regulation of activa-
tion of the complement and kinin generating system; and
AT-III as well as heparin cofactor II play a central role in
the regulation of blood coagulation (31). Interestingly, ser-
pins also inhibit matrix degrading enzymes, such as cathep-
sins (32). The regulation of matrix degradation may thus
not only be promoted by tissue inhibitors of matrix metallo-
proteinases/MMP imbalance but also accelerated by decreased
levels of certain serpins such as 
 
a
 
2
 
-AP or 
 
a
 
1
 
-PI (33), inhib-
itors of matrix degrading activity. In this manner, strome-
lysin-3, despite possessing weak direct matrix degrading ca-
pabilities, might yet play a crucial role in matrix turnover.
Serpins play critical roles in maintaining homeostasis.
Therefore, any mechanism that reduces the functional level
of members of this superfamily, including inactivation by
proteinases, may result in substantial pathological problems
(23, 24). Several of the functions listed above relate to ath-
erosclerosis, and atherosclerotic patients exhibit changes in
the levels of several of these serpins, including 
 
a
 
1
 
-AT, 
 
a
 
2
 
-M
(34, 35), and AT-III (36). In addition, animal studies indi-
cate a potential role of serpins in the inhibition of arterial
intimal thickening (37) and atherosclerotic plaque develop-
ment post injury (38) in vivo. For these reasons, the present
study analyzed the expression of stromelysin-3 within hu-
man atherosclerotic lesions.
Although the expression of stromelysin-3 at sites of
pathologic processes such as Alzheimer’s disease or cancer
has prompted great interest in its regulation, little is known
about the mechanisms involved (11, 39, 40). The strome-
lysin-3 gene promoter differs markedly from previously de-
scribed matrix metalloproteinase promoters as it lacks a
consensus activator protein 1 binding site and has a func-
tional retinoic acid responsive element. We recently dem-
onstrated the presence of the immune mediators CD40
ligand (CD40L) and its receptor CD40 on endothelial cells
(EC), smooth muscle cells (SMC), and macrophages (MØ)
within human atherosclerotic lesions (41) and showed that
ligation of CD40 induces de novo synthesis of the classical
MMP interstitial collagenase (MMP-1) and the gelatinases
A and B (MMP-2 and -9, respectively) (42, 43) in these cells.
 
Therefore, this study also tested the hypothesis that CD40
signaling regulates the expression of the constitutively ac-
tive matrix metalloproteinase stromelysin-3 in human
atheroma-associated cells and in mouse atheroma in vivo.
We report here that (a) stromelysin-3 (MMP-11) is
present in human atherosclerotic lesions in situ, (b) cul-
tured human vascular EC, SMC, and MØ synthesize
stromelysin-3 de novo upon stimulation with CD40L, and
(c) interruption of CD40–CD40L signaling in hyperlipi-
demic mice diminishes stromelysin-3 expression in athero-
sclerotic lesions in vivo.
 
Materials and Methods
 
Materials.
 
Human recombinant IL-1
 
b
 
, TNF
 
a
 
, and IFN
 
g
 
were obtained from Endogen. Phorbol-12 myristate 13-acetate
(PMA) and polymyxin B were purchased from Sigma Chemical
Co. Human recombinant CD40L (rCD40L) was generated as de-
scribed previously (44) and the mouse anti–human stromelysin-3
antibody 5ST-4A9 was produced in a program sponsored by
Bristol Myers Squibb and is subject of an issued U.S. utility
patent number 5484726 (45). Experiments employing rCD40L
were performed in the presence of polymyxin B. Anti-CD40L, a
rat mAb IgG2 antibody raised against mouse CD40L was pre-
pared as described (46) and provided by Immunex Corp. Rat IgG
salt-free crystalline powder (Sigma Chemical Co.), reconstituted
in pyrogen-free normal saline and sterile filtered, was obtained
from Immunex Corp. Both rat anti–mouse CD40L antibody and
rat IgG contained 
 
,
 
2 pg/
 
m
 
l of endotoxin. Anti–human CD40 as
well as control IgG1 mAb (FITC conjugated) used for immuno-
histochemistry were obtained from PharMingen. Low density li-
poprotein receptor–deficient (LDLR
 
2
 
/
 
2
 
) mice (B6/129LDRr-
tm1Her) were obtained from Jackson Laboratory.
 
Cell Isolation and Culture.
 
Human vascular EC were isolated
from saphenous veins by collagenase treatment (1 mg/ml; Wor-
thington Biochemicals) and cultured in dishes coated with fi-
bronectin (1.5 
 
m
 
g/cm
 
2
 
; New York Blood Center Reagents).
Cells were maintained in medium 199 (M199; BioWhittaker)
supplemented with 1% penicillin/streptomycin (BioWhittaker),
5% fetal bovine serum (FBS) (Atlanta Biologicals), 50 
 
m
 
g/ml
heparin (Sigma Chemical Co.), and endothelial cell growth factor
(Pel-Freez Biological). SMC were isolated from human saphe-
nous veins by explant outgrowth (47) and cultured in DMEM
(BioWhittaker) supplemented with 1% 
 
l
 
-glutamine (BioWhit-
taker), 1% penicillin/streptomycin, and 10% FBS. Both cell types
were subcultured following trypsinization (0.5% trypsin [Wor-
thington Biochemicals]/0.2% EDTA [EM Science]) in 75 cm
 
2
 
culture flasks (Becton Dickinson) and used throughout passages
two to four. Culture media and FBS contained 
 
,
 
40 pg endo-
toxin/ml as determined by chromogenic Limulus amoebocyte as-
say analysis (QLC-1000; BioWhittaker). EC and SMC were
characterized by immunostaining with anti von Willebrand factor
and anti SMC 
 
a
 
-actin antibody (Dako), respectively. Both cell
types were cultured 24 h before the experiment in media lacking
FBS: vascular EC were cultured in M199 supplemented with
0.1% human serum albumin and vascular SMC cultured in insu-
lin/transferrin medium as described previously (48).
Mononuclear phagocytes were isolated by density gradient
centrifugation (49), using lymphocyte separation medium (Orga-
non-Teknika), and subsequent counterflow elutriation from
freshly prepared human PBMCs obtained from leukopacs of
healthy donors (provided by Steve K. Clinton, Dana-Farber Can- 
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cer Institute, Boston, MA). Mononuclear phagocytes were used
directly (monocytes) for the experiments or cultured for 1, 3, or
9 d (MØ) in RPMI 1640 containing 2% human serum (Sigma
Chemical Co.). The purity of monocytes/MØ was 
 
$
 
96%, as de-
termined by FACS
 
®
 
 analysis (anti–human CD68 mAb FITC;
PharMingen). For certain studies, MØ were stimulated in RPMI
1640 lacking serum.
Freshly isolated human CD4
 
1
 
 T cells were a gift from Dr. F.W.
Luscinskas (Brigham and Women’s Hospital, Boston, MA). The
purity of CD4
 
1
 
 T cells was 
 
$
 
98%, as determined by FACS
 
®
 
analysis (anti–human CD4 mAb FITC; Calbiochem). Human
CD4
 
1
 
 T cells were activated with PMA (50 ng/ml, 12 h) and
CD40L cell surface expression confirmed by FACS
 
®
 
 analysis us-
ing FITC-labeled anti–human CD40L mAb (Calbiochem). Fi-
nally, activated CD4
 
1
 
 T cell membranes were prepared as de-
scribed previously (42) and used for stimulation at a ratio of T
cells to SMC/EC/MØ of 10:1.
 
Immunohistochemistry.
 
Surgical specimens of human carotid
atheroma and aorta were obtained by protocols approved by the
Human Investigation Review Committee at the Brigham and
Women’s Hospital. Serial cryostat sections (5 
 
m
 
m) were cut, air
dried onto microscope slides (Fisher Scientific), and fixed in ace-
tone at 
 
2
 
20
 
8
 
C for 5 min. Sections were preincubated with PBS
containing 0.3% hydrogen peroxidase activity. The sections were
then incubated (90 min) with primary or control (mouse my-
eloma protein MOPC-21; Sigma Chemical Co.) antibody di-
luted in PBS supplemented with 5% appropriate serum. After
washing three times in PBS, sections were incubated with the re-
spective biotinylated secondary antibody (45 min; Vector) fol-
lowed by avidin–biotin–peroxidase complex (Vectastain ABC
kit; Vector), and antibody binding was visualized with 3-amino-
9-ethyl carbazole (Vector) according to the recommendations
provided by the supplier. For colocalization of stromelysin-3
with CD40 or the respective cell type, double immunofluores-
cence staining was performed. The anti–human stromelysin-3
mAb (1:200) was applied for 60 min followed by biotinylated
anti–mouse secondary antibody for 45 min and Texas red–conju-
gated streptavidin (Amersham). Subsequent to application of the
avidin–biotin blocking kit (Vector), rabbit–anti human CD40 an-
tibody (1:250; Santa Cruz), anti-muscle actin mAb for SMC
(Enzo Diagnostics), anti-CD31 mAb for EC (1:400, Dako), or
anti-CD68 mAb for MØ (1:600; Dako) were added and sec-
tions incubated overnight at 4
 
8
 
C. Subsequently, the appropriate
secondary antibodies were applied for 30 min followed by
Streptavidin–FITC (Amersham). To detect stromelysin-3 in mouse
atherosclerotic lesions, the stromelysin-3 mAb and a specific anti–
mouse absorbed rat biotinylated secondary antibody (1:500), fol-
lowed by avidin–biotin–peroxidase complex, were applied.
 
Biochemical Analysis of Human Atherosclerotic Lesions.
 
Frozen tis-
sue from five nonatherosclerotic arteries and seven atheromatous
carotid plaques were homogenized (IKA-Labortechnik, Ultra-
turrax T 25) and lysed (0.3 mg tissue/ml lysis buffer) as described
previously (5). The lysates were clarified (16,000 
 
g
 
, 15 min) and
the protein concentration for each tissue extract as well as for the
cell culture samples was determined using a bicinchoninic acid
protein assay according to the instructions of the manufacturer
(Pierce). 50 
 
m
 
g total protein were applied to Western blot analysis.
 
In Situ Hybridization.
 
In situ hybridization was performed ac-
cording to the instructions of the manufacturer (Hyb-Probe™;
Shandon/Lipshaw). Frozen tissue sections, obtained as described
above, were fixed in cold acetone, air-dried, and incubated with
a mixture of FITC labeled stromelysin-3–specific (5
 
9
 
-GGTACCG-
TCAACCAGGTCCTCGTCCACG-3
 
9
 
; 5
 
9
 
-CTCAGAGTCGG-
 
GTCTACTGACCGTCC-3
 
9
 
; 5
 
9
 
-CCTACTGGTCCCGTGTCT-
GGACGACGTCCA-3
 
9
 
; 5
 
9
 
-ACGGTCCGGTGCTTATAGTCC-
GATCTCCTGG-3
 
9
 
), CD40L-specific (5
 
9
 
-TTATGGGTGTCAA-
GGCGGTTTGGAACGCCCGTT-3
 
9
 
; 5
 
9
 
-TGAAAAACGACA-
CATAGAAGTATCTTCCAA-3
 
9
 
; 5
 
9
 
-TACTAGCTTTGTATG-
TTGGTTTGAAGAGGGGCT-3
 
9
 
; 5
 
9
 
-TGCAGGAAACCGAAT-
GAGTTTGAGACTTGT-3
 
9
 
), or random oligomers in hybridiza-
tion buffer (30% formamide, 0.6 M NaCl
 
2
 
, 10% dextran sulfate,
50 mM Tris [pH 7.5], 0.1% sodiumpyrophosphate, 0.2% Ficoll, 5
mM EDTA) for 10 min at 65
 
8
 
C and subsequently for 2 h at 37
 
8
 
C
in a moist chamber. Thereafter, slides were immersed in TBS/
Triton (50 mM Tris, 150 mM NaCl, pH 7.6/0.1% Triton
X-100) to allow coverslips to float off and were washed (TBS/
Triton) three times for 3 min at 37
 
8
 
C. The slides were forwarded
to the immunological reaction by incubation with blocking solu-
tion (10 min, rt) and subsequent addition of the alkaline phos-
phatase–conjugated rabbit Fab
 
9 anti FITC (30 min, rt, moist
chamber) as the primary detection reagent. Finally, the slides
were washed twice in TBS (3 min, rt), covered with alkaline
phosphatase substrate buffer (5 min, rt), and developed using the
NBT/BCIP (nitro-blue-tetrazolium/5-bromo-4-chloro-3-indolyl
phosphate) chromogen solution (1–2 h, rt, moist chamber).
Western Blotting and Radioimmunoprecipitation. Cell extracts
(25  mg total protein/lane) and culture supernatants were sepa-
rated by standard SDS-PAGE under reducing conditions and
blotted to polyvinylidene difluoride membranes (Bio-Rad) using
a semidry blotting apparatus (0.8 mA/cm2, 30 min; Bio-Rad).
Blots were blocked and first and second monoclonal antibodies
were diluted in 5% defatted dry milk/PBS/0.1% Tween 20. After
1 h of incubation with the respective primary antibody, blots
were washed three times (PBS/0.1% Tween 20) and the second-
ary, peroxidase–conjugated, goat anti–mouse antibody (Jackson
ImmunoResearch) was added for another hour. Finally, the blots
were washed (20 min, PBS/0.1% Tween 20) and immunoreac-
tive proteins were visualized using the Western blot chemilumi-
nescence system (NEN™).
For radioimmunoprecipitation experiments, cells were washed
and further incubated with unlabeled medium lacking methio-
nine/cysteine. Subsequently, medium containing 10% FBS and
50 mCi/ml [35S]methionine/cysteine (NEN™) was added to the
cells for 24 h. Supernatants were harvested and concentrated
(103) using Centricon 3 devices (Amicon). Immunoprecipita-
tion buffer (50 mM Tris-HCl, 0.1% SDS, 0.1% sodium deoxy-
cholate, 1% NP-40, 150 mM NaCl, 5 mM EDTA, 20 mg/ml
soybean trypsin inhibitor, 0.1% mM PMSF, 0.2 U/ml aprotinin,
0.025% sodium azide) was added to the cultures and cells were
harvested by scraping. Subsequently, non immune mouse serum
(Vector) was added (24 h, 48C) to preclear the samples. Antigens
in supernatants and cell extracts were immunoprecipitated with
the specific anti stromelysin-3 antibody 5ST-4A9 (2 h, 48C) and
pelleted by subsequent addition of rabbit anti–mouse IgG (18 h,
48C) as well as protein A–Sepharose beads (2 h, 48C). The beads
were washed four times in 50 mM Tris-HCl and finally 50 ml
SDS-PAGE loading buffer (200 mmol/liter Tris, 5% glycerol,
0.1% SDS, 3% b-mercaptoethanol, 0.1 mg/ml bromophenol
blue) was added. After heating the samples 5 min at 958C, super-
natants were separated by SDS-PAGE and transferred to polyvi-
nylidene difluoride membranes. Blots were dried and exposed to
x-ray film for detection of the immunoprecipitated antigen.
Isolation of RNA and PCR. Total RNA from unstimulated or
stimulated (24 h) EC, SMC, or MØ was isolated by a one-step
preparation according to the method of Chomczynski and Sacchi
(50). The cDNA was prepared by reverse transcription (RT) of846 Expression of Stromelysin-3 in Human Atheroma
total RNA (1 mg) with oligo(dT) using superscript reverse tran-
scriptase (GIBCO BRL). The RT products were diluted in 480 ml
twice distilled water and 10 ml of these cDNA preparations were
mixed on ice with 10 ml primers (20 mM), 80 ml reaction mix
(including 10 ml of PCR buffer, 2.5 mM MgCl), 4 ml dNTPs
(200 mM; final concentration), and 0.5 ml Taq-polymerase (2.5 U;
all GIBCO BRL). PCR was performed for 35 cycles at 958C
(120 s), 628C (120 s), and 728C (180 s, 2 s prolongation per cycle)
after hot start. The sequences of primers for human stromelysin-3
were 59-CTGCAGTCATCTGGGCTGAGACTC-39 and 59-
CCATGGCAGTTGGTGCAGGAGCAG-39. The primers were
obtained from Integrated DNA Technologies. Aliquots of the
PCR products were run on 1.3% agarose gels and visualized by
UV transillumination.
In Vivo Analysis of CD40L-mediated Stromelysin-3 Expression.
LDLR2/2 at a minimum age of 8 wk were fed a high cholesterol
diet (1.25% cholesterol, 0% cholate; Research Diets) and treated
for a period of 12 wk with either rat IgG (control) or rat anti–
mouse CD40L (M158) antibody (both at 250 mg per mouse
twice a week intraperitoneal; both provided by Immunex Corp.)
(51). Thereafter, the mice (10 per group) were killed, the aortic
arches embedded, and tissue sections examined by immunohis-
tochemistry as described below. The extent of lesion formation
Figure 2. Colocalization of stromelysin-3
with endothelial cells, smooth muscle cells,
and macrophages in human atheroma. High
power views (3400) of frozen sections of
human carotid lesions showed specific stain-
ing for stromelysin-3 (right, red staining) on
human vascular endothelial cells (EC),
smooth muscle cells (SMC), and macro-
phages (MØ) within the plaque. Cell types
were characterized by immunofluorescence
double staining (left, green staining) as de-
scribed in Materials and Methods. The lu-
men of the artery is at the top of each photo-
micrograph. Analysis of seven atheroma
from different donors showed similar results.
ducing conditions and analyzed by Western blotting for stromelysin-3 ex-
pression. The positions of the molecular mass markers are indicated (kD).
Analysis of five normal tissues as well as seven atheromatous lesions from
different donors showed similar results.
Figure 1. Expression of stromelysin-3 in human atherosclerotic
plaques. (A) Frozen sections of normal human arterial tissue and human
atheromatous plaques were stained for stromelysin-3. The tissue was ana-
lyzed using horseradish peroxidase–mediated immunohistochemistry on
adjacent sections (red reaction product). No immunoreactivity was ob-
served in tissue stained with the respective control IgG1 antibody (data
not shown). The lumen of the artery is at the top of each photomicro-
graph (3100). Analysis of five normal aortic tissue and seven atheroma
obtained from different donors showed similar results. (B) Extracts (50
mg/ml) of three nonatherosclerotic tissue (Normal) and atheromatous
plaques (Atheromatous) were separated by standard SDS-PAGE under re-847 Schönbeck et al.
and the expression of vascular adhesion molecule-1 in these animals
has been reported separately (51). No difference in the serum lipid
profiles (total cholesterol, very low density lipoprotein, low density
lipoprotein, and high density lipoprotein [analyzed by fast protein
liquid chromatography] or triglycerides) or in circulating leuko-
cytes, hematocrit, or body weight was observed among the groups.
Results
Expression of Stromelysin-3 in Human Atherosclerotic
Plaques. Immunohistochemical analysis of the expression
of stromelysin-3 in normal aortic specimens (n 5 5; Fig. 1 A,
left) and human atherosclerotic fatty streaks (n 5 5; data
not shown) revealed little or no expression of the enzyme.
In contrast, well-developed human carotid atherosclerotic
lesions (n 5 7) consistently showed strong stromelysin-3
immunoreactivity, most prominently at the luminal border
and in the shoulder region of the plaque (Fig. 1 A, right).
Western Blot analysis, performed on protein extracts of the
surgical specimens and using the identical antibody used for
the immunohistochemistry studies, revealed barely detect-
able immunoreactive stromelysin-3 in control specimens
but markedly increased levels of the proteinase in athero-
sclerotic tissue (Fig. 1 B). The immunoreactive bands de-
tected had molecular masses of z64, 48, 35, and 28 kD,
corresponding to the zymogen, intermediate, and active
forms of stromelysin-3 (9, 10, 22, 23, 52, and 53). Higher
magnifications of the immunohistochemical analysis, as
well as immunofluorescent double staining with respective
cell-selective antibodies, localized stromelysin-3 within
EC, SMC, and MØ of the plaque (Fig. 2). Tissues showed
no staining with the respective control IgG1 antibody (data
not shown). Because we recently localized CD40 and
CD40L in human atherosclerotic plaques and have shown
that CD40 ligation induces interstitial collagenases and ge-
latinases in atheroma-associated cells (41–43), we investi-
gated the possible colocalization of stromelysin-3 with
CD40. Indeed, cells expressing stromelysin-3 also bear
CD40 (Fig. 3). Furthermore, we analyzed the cellular lo-
calization of stromelysin-3 transcripts by in situ hybridiza-
tion (Fig. 4). Human atheroma (Fig. 4, C–E), but not nor-
mal arteries (Fig. 4, A and B), contained stromelysin-3
mRNA. Within the atherosclerotic lesion, stromelysin-3
Figure 3. Colocalization of stromelysin-3 with CD40 in human ath-
erosclerotic lesions. Frozen sections of normal human atheromatous
plaques were stained for stromelysin-3 and CD40 by immunofluores-
cence double staining (stromelysin-3 in red, CD40 in green). No immu-
noreactivity was observed in tissue stained with the respective control
IgG1 antibody (data not shown). The lumen of the artery is at the top of
each photomicrograph (3100). Analysis of five normal aortic tissue and
seven atheroma obtained from different donors showed similar results.
Figure 4. Human stromelysin-3 mRNA colocalizes with EC, SMC,
and MØ of the atherosclerotic lesion. In situ hybridization analysis of
nonatherosclerotic tissue (A and B) revealed no detectable stromelysin-3
mRNA signal, in contrast to atheromatous plaques (C–E). Higher magni-
fication (3400) of stromelysin-3 mRNA-positive areas revealed colocal-
ization with MØ-like (D), as well as EC- and SMC-like (E) cell types
within the lesion. Negative control probes yielded no detectable signal
(F). Areas of the plaque and cell types similar to those found positive for
stromelysin-3 stained also for CD40L mRNA (G and H). Analysis of
three atheroma from different donors showed similar results.848 Expression of Stromelysin-3 in Human Atheroma
transcripts localized most prominently at the luminal bor-
der and the shoulder region of the plaques, areas described
above as positive for the immunoreactive protein. The
staining for the transcripts colocalized with smooth muscle
cell- and macrophage-like cells (Fig. 4, D and E) as well
as the endothelium (Fig. 4 E). Furthermore, transcripts for the
immune mediator CD40L showed a similar distribution on
adjacent sections (Fig. 4, G and H). In situ hybridization with
negative control probes did not yield any signal (Fig. 4 F).
Ligation of CD40 on Human Vascular Endothelial and SMC
as well as MØ Induces De Novo Expression of Stromelysin-3.
To determine the mechanisms involved in stromelysin-3
expression in atheroma-associated cells, we analyzed the
expression of the enzyme in human vascular EC and SMC
as well as in human mononuclear phagocytes in vitro. Hu-
man vascular EC, SMC, and MØ released immunoreactive
stromelysin-3 constitutively in moderate amounts. Stimula-
tion of the cells with the classical mediators of MMP regu-
lation, IL-1 (1 and 10 ng/ml), TNF-a (5 and 50 ng/ml), or
IFNg (100 and 1,000 U/ml), did not affect the expression
of stromelysin-3, as illustrated here for IL-1 and SMC (Fig.
5). However, the immunohistochemical studies presented
above indicated possible involvement of the CD40–
CD40L signaling pathway. Stimulation with both T cell–
derived as well as recombinant human CD40L induced
stromelysin-3 expression in all three cell types (Figs. 5 and
6). Besides an increased intensity of the higher (z64 kD)
molecular mass band, which corresponds to the molecular
mass of the stromelysin-3 zymogen, CD40 ligation induced
the expression of immunoreactive proteins of lower molec-
ular mass, corresponding to the molecular mass of the ac-
tive cleavage products of the zymogen (Fig. 5). In control
experiments, addition of blocking anti-CD40L antibody
during stimulation of the cells with native or recombinant
ligand inhibited induction of stromelysin-3 expression.
Among the cell types analyzed, the immunoreactive
forms of stromelysin-3 detected after CD40 ligation
showed slight differences in the intensity of the respective
bands but were identical in molecular mass. In vascular
SMC, CD40 ligation concentration and time dependently
elevated expression of the 64-kD protein, as well as in-
duced immunoreactive proteins with molecular masses of
z48 and z28 kD. The induction of the lower molecular
mass forms of stromelysin-3 in cultures of SMC required
stimulation with 3–10 mg/ml rCD40L (Fig. 6 A). An in-
crease in the 64-kD protein, as well as in the z48-kD im-
munoreactive protein, occurred after 1 h of stimulation,
whereas detection of the 28-kD band required at least 6–12 h
of exposure to CD40L, as determined by Western blot
analysis (data not shown) and radioimmunoprecipitation
experiments (Fig. 7). The patterns of immunoreactive pro-
teins detected in cultures of vascular smooth muscle cells
resembled those found in fibroblasts, an established source
of stromelysin-3 (data not shown). The pattern of immu-
noreactive bands observed with supernatants of CD40L-
stimulated EC (Fig. 6 B) resembled that obtained with cul-
tures of SMC, except that the 64-kD form was much less
abundant in EC.
Macrophages, derived from monocytes cultured for 9 d,
showed an additional immunoreactive protein at z35 kD.
Figure 5. CD40L induces stromelysin-3 in human vascular smooth
muscle cells in vitro. Human vascular SMC, cultured 24 h before the ex-
periment in insulin/transferrin medium, were incubated (24 h) with
membranes of 50 ng/ml PMA-stimulated (12 h) CD41 T lymphocytes (T
cell membranes, ratio equivalent to 1 SMC:10 T cells), 1 or 10 mg/ml re-
combinant human CD40 ligand (rCD40L), or 10 ng/ml IL-1b in the ab-
sence or presence of an anti-CD40L antibody (1 mg/ml a-CD40L). Con-
centrated (103) supernatants were analyzed by Western blotting for
stromelysin-3 protein expression. The positions of the molecular weight
markers are indicated (kD). Data shown are representative of three exper-
iments performed with SMC from different donors.
Figure 6. CD40L induces stromelysin-3 in atheroma-associated cells in
a concentration dependent fashion. Human vascular smooth muscle cells
(SMC), endothelial cells (EC), monocyte–derived macrophages after 9 d
in culture (MØ), and freshly isolated peripheral blood monocytes
(PBMC), cultured 24 h before the experiment in the respective serum-
free medium, were incubated (24 h) with the respective concentrations of
recombinant human CD40 ligand (rCD40L). Concentrated (103) super-
natants were analyzed by Western blotting for stromelysin-3 protein ex-
pression. For specificity control, the primary antibody was blocked (1 h,
378C) with recombinant stromelysin-3 (10 mg/ml) before applied to par-
allel samples of supernatants of 3 mg/ml rCD40L–stimulated cultures
(blocking, right lanes). The positions of the molecular mass markers are
indicated (kD). Data shown are representative of three to six experiments
performed with cells from different donors.849 Schönbeck et al.
Stimulation with $0.3 mg/ml rCD40L increased levels of
immunoreactive proteins with apparent molecular masses
of 64, 48, 35, and 28 kD (Fig. 6 C). Induction of these im-
munoreactive bands required at least 6 h of stimulation
(data not shown). Specificity of the antibody used was con-
firmed by Western blot analysis performed with the anti-
stromelysin-3 antibody preincubated with recombinant
stromelysin-3 (Fig. 6, blocking). In contrast to monocyte-
derived MØ cultured for 9 d, freshly isolated peripheral
blood monocytes expressed stromelysin-3 neither constitu-
tively nor when stimulated with rCD40L (Fig. 6 D). Re-
sponsiveness of monocyte-derived cells to CD40 ligation
required a minimum of three days of in vitro culture (data
not shown).
The stromelysin-3 expression induced by CD40 ligation
in human vascular EC, SMC, and MØ resulted from de
novo synthesis of the protein. Metabolic labeling and im-
munoprecipitation experiments yielded autoradiographic
bands resembling the patterns of immunoreactive proteins
observed by Western blot analysis as shown here for vascu-
lar SMC (Fig. 7). In accordance with our protein analysis,
RT-PCR experiments showed increased product corre-
sponding to stromelysin-3 transcript after CD40 ligation in
EC and SMC as well as MØ (data not shown).
Interruption of CD40–CD40L Signaling Diminished Stro-
melysin-3 Expression in Mouse Atherosclerotic Lesions. The in
situ observations of stromelysin-3 expression in human
atherosclerotic plaques, in combination with the in vitro
findings that CD40 ligation selectively mediates the expres-
sion of stromelysin-3, suggested an in vivo evaluation of
the importance of CD40–CD40L signaling for the expres-
sion of this enzyme within atherosclerotic plaques. For this
purpose, an established animal model of arteriosclerosis was
used: LDLR2/2 mice were fed a high cholesterol (1.25%)
diet to develop atherosclerotic lesions (51). Immunohis-
tochemical analysis of lesions within the aortic arch as well
as the thoracic portion of the aorta revealed a stromelysin-3
expression pattern similar to that found in human athero-
sclerotic plaques. All three vascular cell types—EC, SMC
and MØ—within the lesions stained for the proteinase.
Treatment of the mice with rat IgG (n 5 8) did not affect
the stromelysin-3 expression (Fig. 8 A) compared to con-
trols. In contrast, mice treated with the anti–mouse CD40L
antibody (n 5 8) showed substantially reduced immunore-
activity for stromelysin-3 within the atherosclerotic lesions
(Fig. 8 B). Since the anti-CD40L antibody treatment also
resulted in a decrease of total plaque number and area (51),
lesions of similar sizes within the treatment groups were
compared. No immunoreactivity was observed in tissues
stained with the control IgG1 antibody (data not shown).
Discussion
This study establishes the expression of stromelysin-3 in
advanced human atheroma and furthermore provides evi-
dence for (a) colocalization of this matrix metalloproteinase
with CD40 on lesional EC, SMC, and MØ in situ and (b)
regulation of de novo expression of stromelysin-3 by
CD40 ligation, rather than by the classical soluble media-
tors of MMPs such as IL-1, TNF-a, or IFN-g. We also
demonstrated in vivo that the interruption of CD40–
CD40L interaction markedly reduced the expression of
stromelysin-3 in mouse atheroma. The finding that EC,
SMC, and MØ express stromelysin-3 establishes atheroma-
Figure 7. CD40 ligation in-
duces de novo stromelysin-3 ex-
pression in human vascular
SMC. Human vascular SMC,
cultured 24 h before the experi-
ment in DMEM lacking me-
thionine/cysteine, were incu-
bated for the indicated times
with 10 mg/ml rCD40L in the
presence of 50 mCi/ml [35S]me-
thionine/cysteine. Antigen was
immunoprecipitated from con-
centrated (103) culture superna-
tants with the specific anti-
stromelysin-3 antibody and blots were dried and exposed to x-ray film for
detection. The positions of the molecular mass markers are indicated
(kD). Data shown are representative of three experiments performed with
SMC obtained from different donors.
Figure 8. Interruption of CD40–CD40L signaling in hyperlipidemic
LDLR2/2 mice reduces stromelysin-3 expression in atherosclerotic
plaques. High power views of frozen sections of aorta from LDLR2/2
mice fed a high cholesterol diet and treated with rat IgG for control (IgG)
or rat anti–murine CD40L antibody (a-CD40L) (both at 250 mg/ml, in-
traperitonally, twice per week) are shown. Plaques of approximately sim-
ilar size were chosen for comparison. The lumen of the artery is at the top
of each photomicrograph. Analysis of aortas obtained from eight different
mice of each group showed similar results.850 Expression of Stromelysin-3 in Human Atheroma
associated cells as novel sources of stromelysin-3. Thus, this
report provides evidence that stromelysin-3, whose expres-
sion correlates with the invasiveness of malignancies (3, 11,
12, 16, 17, 54), might also participate in the pathogenesis of
another common human disease, atherosclerosis. In view of
its unusual substrate specificity, stromelysin-3 might partic-
ipate in several pathways. The pattern of stromelysin-3 ex-
pression within tissues that undergo extensive remodeling
in pathological (carcinomas; 11, 12, 16, 17, 54) as well as
physiological (placenta and uterus; 11, 18) events, indicates
a role for stromelysin-3 in these processes. Although related
by sequence to the MMP family, stromelysin-3 does not
hydrolyze many of the extracellular matrix components
that are substrates for other MMPs such as fibronectin,
laminin, elastin, or collagen type I and type IV (23). From
this perspective, the enzyme has been considered a nonma-
trix–degrading metalloproteinase. Instead, stromelysin-3
appears to act as a predominant regulator of serpin func-
tion. Interestingly, a recent report postulated that extracel-
lular matrix degradation might depend not only on an
imbalance between matrix metalloproteinases and their
inhibitors, but might accelerate in face of decreased levels
of certain serpins such as a2-M,  a2-AP, or a1-PI (33),
preferred substrates of stromelysin-3 (23). Pathways by
which this enzyme might regulate matrix degradation in-
clude (a) inactivation of matrix-degrading, enzyme-inhi-
biting serpins as described for cathepsins (32) or for elas-
tolytic activity by a1-PI, shown to simultaneously augment
the proliferative and invasive activity of cells (23); (b)
activation of other members of the MMP family (17) copi-
ously expressed in atheroma, such as interstitial collagenase,
gelatinases A and B, and stromelysin-1 (5) (at sites of
chronic inflammation, such as atherosclerosis, constitutively
active stromelysin-3 [9] might act proximally to promote
conversion of the zymogen forms of these classical MMPs
to their active forms); and (c) degradation of matrix mole-
cules not cleaved by the classical MMPs such as extracellu-
lar proteins containing amino acids with unusual long side
chains, including those generated in vivo by certain post-
translational modifications (55). Thus, matrix degradation,
a critical step in the progression from the stable atheroma
to one prone to rupture and capable of causing thrombotic
complications, might indeed involve the action of stro-
melysin-3. The serpin-degrading function of stromelysin-3
may thus have significance beyond tumor invasion and
metastasis.
Furthermore, the action of stromelysin-3 on serpins also
might affect atherosclerosis by pathways other than extra-
cellular matrix remodeling. Serpins regulate multiple func-
tions associated with the disease, including (a) blood pres-
sure (e.g., the serpin a1–antitrypsin inhibits renin and thus
renin–angiotensinogen interaction, as well as angiotensino-
gen itself [30]), (b) fibrinolysis (e.g., the serpin a1–antiplas-
min targets plasmin, a key effector of fibrinolysis [23]), (c)
blood coagulation (e.g., the serpins anti-thrombin III and
heparin cofactor II rapidly interact with thrombin in the
presence of heparin [31]), or (d) lipoprotein uptake (cleav-
age of the serpins a1-antitrypsin and a2-macroglobulin is
associated with increased low density lipoprotein uptake
into cells, indicating that those cleaved serpins disturb the
intracellular cholesterol homeostasis [27–29]). Aside from
these effects, stromelysin-3 might further affect atheroscle-
rosis via the insulin-like growth factor–insulin-like growth
factor binding protein (IGF–IGFBP) system. Human ather-
oma contain IGF-1 and IGFBPs (56). These mediators are
associated with cardiovascular pathophysiology particularly
via their critical role in vascular growth (57). IGF-1 directly
accelerates arteriosclerosis in rat aorta allografts via myointi-
mal proliferation and intimal thickening (58). The level of
free, biologically active IGF-1 depends on the degree of
complex formation with the respective binding proteins. A
recent study identified IGFBP-1 as a potential physiological
substrate for human stromelysin-3 (59). Finally, IGF also acts
as a survival factor for human vascular SMC derived from
normal vessels as well as coronary atherosclerotic plaques
(60), suggesting stromelysin-3 may prevent apoptosis of vas-
cular SMC by augmenting IGF-1 levels.
The potential relevance of serpin degradation for the
pathogenesis of atherosclerosis in humans is supported by
reports showing that levels of several serpins, including
AT-III (36), a2-M, and a2-AP (35), decrease in this preva-
lent disease. In addition, recent in vivo studies demon-
strated that serpins inhibit coronary restenosis in atheroscle-
rotic swine (37) and atherosclerotic plaque development in
rabbits post injury (38). Our findings that (a) differentiated
atherosclerotic lesions but not their precursor, the fatty
streak, bear stromelysin-3; (b) the immunoreactive bands
detected within the atheromatous plaques resembled
mostly the pattern obtained with MØ in vitro; and (c) only
differentiated MØ, but not peripheral blood monocytes,
exhibit stromelysin-3 induction; support a role of this en-
zyme in the late rather than the early states of atherosclero-
sis. Interestingly, the Rotterdam study showed increased
AT-III levels in moderate peripheral arterial atherosclerosis
and decreased levels in more severe atherosclerosis (61).
Future studies will have to establish whether these vari-
ous functions apply to human atherosclerosis and whether
stromelysin-3 is the crucial mediator in reduction of all or
only certain atheroma-associated serpin activities. How-
ever, based on the recently burgeoning background infor-
mation on stromelysin-3, our findings suggest functions of
this proteinase in regulation of plaque progression and
(in)stability by mechanisms distinct from those ascribed to
members of the MMP family, including augmented extra-
cellular matrix degradation, promotion of blood coagula-
tion, decreased fibrinolytic activity, and dysregulation of
blood pressure as well as lipoprotein catabolism. The colo-
calization of stromelysin-3 with CD40 and CD40L within
the human atherosclerotic lesion, as well as the demonstra-
tion that CD40L, rather than the classical mediators of
MMPs, induce stromelysin-3 expression in atheroma-asso-
ciated cells demonstrate CD40–CD40L signaling as a new,
and, as indicated by the in vivo studies, probably crucial
pathway of stromelysin-3 induction.851 Schönbeck et al.
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